Adial Pharmaceuticals (ADIL) Retained Earnings (2017 - 2026)
Adial Pharmaceuticals (ADIL) posted Retained Earnings of -$92.0 million for Q1 2026, down 2.25% sequentially from -$90.0 million in Q4 2025, and down 9.23% YoY from -$101.3 million in Q1 2025.
Adial Pharmaceuticals (ADIL) Retained Earnings (2017 - 2026) Analysis & Trends
Adial Pharmaceuticals has reported Retained Earnings for 10 years, with the latest figure at -$92.0 million in Q1 2026.
- Quarterly Retained Earnings fell 9.23% year-over-year to -$92.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$92.0 million (down 9.23% YoY) and the FY2025 annual result came in at -$90.0 million, down 204.54% from the prior year.
- Retained Earnings slipped to -$92.0 million in Q1 2026 per ADIL's latest filing, from -$90.0 million in the prior quarter.
- Over five years, Retained Earnings peaked at $86.1 million in Q4 2024 and troughed at -$92.0 million in Q1 2026.
- A 5-year average of -$10.3 million and a median of -$57.7 million in 2022 frame the typical range for Retained Earnings.
- The widest YoY moves for Retained Earnings: up 231.42% in 2022, down 226.52% in 2022.
- Over 5 years, Retained Earnings stood at $66.9 million in 2022, then climbed by 8.86% to $72.9 million in 2023, then climbed by 18.09% to $86.1 million in 2024, then tumbled by 204.54% to -$90.0 million in 2025, then retreated by 2.25% to -$92.0 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$92.0 million, -$90.0 million, and -$88.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.54 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 59.41 Bn | 54.27 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - | 4.38 Bn |
| 10 | Adial Pharmaceuticals | 27.59 Mn | 27.59 Mn | - | -143.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -91.99 Mn |
| Dec 31, 2025 | -89.97 Mn |
| Sep 30, 2025 | -87.98 Mn |
| Jun 30, 2025 | 3.30 Mn |
| Mar 31, 2025 | -84.22 Mn |
| Dec 31, 2024 | 86.06 Mn |
| Sep 30, 2024 | 85.80 Mn |
| Jun 30, 2024 | -77.73 Mn |
| Mar 31, 2024 | -75.27 Mn |
| Dec 31, 2023 | 72.88 Mn |
| Sep 30, 2023 | 69.22 Mn |
| Jun 30, 2023 | 68.81 Mn |
| Mar 31, 2023 | -66.58 Mn |
| Dec 31, 2022 | 66.95 Mn |
| Sep 30, 2022 | -60.81 Mn |
| Jun 30, 2022 | -57.70 Mn |
| Mar 31, 2022 | 64.53 Mn |
| Dec 31, 2021 | -50.94 Mn |
| Sep 30, 2021 | -45.10 Mn |
| Jun 30, 2021 | 45.61 Mn |